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Abstract: Data on biological variation are used for many 
purposes in laboratory medicine but concern exists over 
the validity of the data reported in some studies. A critical 
appraisal checklist has been produced by a working group 
established by the European Federation of Clinical Chemis-
try and Laboratory Medicine (EFLM) to enable standardised 
assessment of existing and future publications of biologi-
cal variation data. The checklist identifies key elements to 
be reported in studies to enable safe accurate and effective 
transport of biological variation data sets across healthcare 
systems. The checklist is mapped to the domains of a mini-
mum data set required to enable this process.
Keywords: biological variation; checklist; critical 
appraisal; reference values.
Introduction
Biological variation data have many applications in lab-
oratory medicine [1]. Those include setting of analytical 
performance specifications based on components of bio-
logical variation [2]. Models attempt to minimise the ratio 
of “analytical noise” to the biological signal within clini-
cal laboratory measurements and to ensure that popula-
tion-based reference intervals are transferable over time 
and geography. If analytical goals are achieved then this 
implies that there is no advantage in further improvement 
of the method in terms of the derived quality standard. 
The valid use of biological variation data (BVD) in this 
and other applications requires that they are robust and 
have characteristics concordant with those of the popula-
tion to which the measurement procedure is to be applied. 
This requires that BVD are appropriately quantified, 
well defined, characterised and understood to enable 
their translation into safe and effective applications 
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and transportability across populations and health care 
systems.
There are parallels to be drawn between the produc-
tion and use of BVD and production and use of reference 
values [3–8]. The requirements for delivery and charac-
terisation of the latter have been clearly identified by the 
International Federation of Clinical Chemistry and Labora-
tory Medicine (IFCC) and more recently in guidance issued 
by the Clinical and Laboratory Standards Institute (CLSI) 
[9]. The approach identifies need for characterisation of 
populations studied, methods for production of data, and 
the statistical treatment of data. A need for this degree of 
definition is accepted in the context of population-based 
reference values and is as important in the context of BVD. 
There are currently no recognised international standards 
for the production and reporting of BVD.
Review of the literature relating to biological variation 
(BV) identifies a significant volume of work stretching back 
over 40 years. The papers published are of varying quality 
in terms of study designs and presentation. This delivers 
a high degree of uncertainty around published estimates 
of BV [10–12]. The heterogeneity in quality of BVD and 
the use of non-standardised terminology to describe the 
data in publications are also problematic [13] and provide 
further complexity for the user. Attempts to make BVD 
accessible to laboratory medicine specialists have resulted 
in the delivery of a biological variation data base by Ricós 
and colleagues which is currently hosted online [14–16]. 
The criteria they used to construct the database have been 
published recently [17]. The authors recognised that there 
is a need to further develop criteria to better characterise 
BVD and enable selection of BVD from publications for 
inclusion in their database. In the absence of such criteria 
compiled data collections are readily available in acces-
sible formats that potentially enable an uncritical applica-
tion of often poorly characterised data sets.
Work has been undertaken to develop the criti-
cal appraisal checklist presented here by the Biologi-
cal Variation Working Group (BVWG) [18] established 
by the European Federation of Clinical Chemistry and 
Laboratory Medicine (EFLM). The checklist is similar to 
that published as part of the Standards for Reporting of 
Diagnostic Accuracy guideline (STARD) which aimed to 
raise the quality of publications in that area [19, 20]. The 
checklist proposed here, by the BVWG, is a tool that will 
assist laboratory medicine professionals to generate and 
publish high quality BVD accompanied by relevant meta-
data to enable safe accurate and effective clinical applica-
tions [21]. It provides a framework for end users of BVD to 
critically appraise existing publications, and for review-
ers of future BVD publications to assure a standard of 
reporting that enables valid clinical application of new 
BVD studies by those same end users. Studies and pub-
lications that are compliant with the checklist will allow 
effective transportability of appropriately derived and 
characterised BVD across health care systems as reference 
data. It follows that valid application of BVD by laboratory 
medicine specialists at other locations or times requires 
recording and transmission of key metadata [22]. Those 
metadata describe and give information concerning the 
key attributes of BVD that impact on transportability 
(e.g., demographics of the population from which they 
were derived, description of the analytical methods used 
etc). The metadata can be further grouped into a defined 
“data archetype” to enable consistency and constancy of 
transmission of BVD through information and knowledge 
management systems as reference data. It has been pro-
posed that definition of BVD as transportable reference 
data requires that key metadata forming the archetype 
can be clearly identified within six domains (e.g., study 
characteristics, population characteristics, and data char-
acteristics) [21, 23]. The key metadata from each of those 
domains delivers a minimum data set (MDS) that can be 
used to define the data archetype as part of a future health 
informatics standard for onward  transmission of BVD.
Adherence to STARD guidelines is required by many 
journals for studies on diagnostic accuracy providing an 
important checklist of items to be included in publications. 
The positive impact of the STARD guidelines has been 
acknowledged by a Consortium of Laboratory Medicine 
Journal Editors [24]. The importance of the detail required 
in publications to enable the insight of readers into the 
value of research is recognised. The Biological Variation 
Data Reporting critical appraisal Checklist (BioVarC) is pro-
posed to deliver a similar approach and benefit. It stands 
as a precursor initiative to production of any formalised 
standards for delivery and reporting of BV studies, being 
based on an evaluation of current best practice and the 
need to ensure incorporation of key metadata into publica-
tions that impact upon the utility of BVD. Such standards 
may enable delivery of a need identified in 1989 by Fraser 
and Harris to be able to ensure comparability of data by 
use of common study design and analysis of data [25].
Materials and methods
The BVWG established by the EFLM consisted of labo-
ratory medicine specialist with a remit to establish a 
critical appraisal checklist for publication of biological 
variation data. The group has studied existing BV litera-
ture and databases and undertaken discussions to enable 
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construction of a critical appraisal checklist applicable to 
existing and future publications of BVD. The group have 
further identified a MDS required by users to enable trans-
portability of BVD into local clinical practice.
Results
The checklist is shown in Table 1. It is based on the same 
structure as the STARD table and identifies six main items 
for focus with a number of sub items. The sub items have 
been additionally mapped to minimum data set domains 
(Table 2; MDS: A–F) previously identified by the BVWG 
[21, 23]. Domain (F), which relates to a data rating concept, 
is not included in the checklist at this time as this is a 
quality measure that requires further development. The 
attributes identified in MDS domains A–E are identified 
as describing key metadata to enable safe, accurate and 
effective use of BVD by third party users. Domains E and 
F will provide further sources of information to support 
a users decision-making processes in the context of their 
clinical practice and support delivery of data through 
media such as online databases.
Table 1: Biological Variation Data Reporting Checklist (BiVarC).
Section and Topic Item #
(MDS Domain 
Mapping: A-F)a
Evidenced
Title/abstract/keywords 1 The title should indicate that the content relates to a study of 
biological variation, the subject of the study, the sample matrix, and 
the population studied.
Analyte (component being measured), the measurand/s (the quantity 
or quantities to be measured, see Section 1.1), and state of well-being 
of the subjects under study should be clearly and unambiguously 
identified. Relevant coding systems might be employed, (e.g., LOINC 
[27], SNOMED [28], C-NPU [29])
Abstract 1.1 As a minimum it should contain the headline biological variation 
data, the major characteristics of the population studied (numbers 
of subjects with demographics), clearly identify the analyte and 
measurand/s studied [the analyte quantities studied in a particular 
sample matrix, (e.g., concentration of glucose in plasma)], the 
statistical approach taken, the duration of the study and the 
geographical location of the study.
Introduction 2 Introduction should clearly identify the context and aims of the 
study and cite any previous relevant studies of biological variability 
of the target analyte. Recommended terminology to be adopted re 
description of variability [13].
Methods 3 Described in enough detail to facilitate transportability of the derived 
data across populations and health care systems. The biological 
variation data produced are effectively reference data and their 
applicability requires delivery of appropriately described metadata to 
enable their use as such.
Analyte/measurand 3.1 (A) The described study should clearly identify the target analyte and 
measurand/s. Where available internationally agreed terminology and 
codings should be utilised.
Subjects 3.2 (B) The description of the subjects and population studied should be 
detailed enough to enable transportability of the biological variation 
data. Minimum data set should be present [21–23]. This should include 
number of subjects studied, age, gender, and state of well-being.
Measurement procedure 3.3 (A) A clear description of the analytical methodology used should form 
part of the metadata. This may be made available via an appropriate 
reference or be presented within the publication. Deviation from 
standard operating procedures, use of adaptations of published 
methods, and deviation from manufacturers recommended methods 
in the case of commercially available systems should be documented. 
Standardisation and traceability should be clearly identified.
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Section and Topic Item #
(MDS Domain 
Mapping: A-F)a
Evidenced
Length of study 3.4 (C) Length of the study periods should be clearly identified.
Sampling 3.5 (C) Sampling protocols (e.g., subject preparation, sampling conditions) 
that minimise pre-analytical variation should be adequately described 
to enable transportability of the data [25]. Numbers of samples taken 
should be sufficient to deliver the required power to the study [25, 
26].
Samples 3.6 (C) Recorded details should include the beginning and end date of the 
study and timings of sampling.
Sampling conditions and sample type should be described in detail. 
Pre-analytical storage conditions of samples should be described.
Conditions for analysis of samples 3.7 (C) A description of conditions under which the samples were analysed. 
Analytical protocols should be designed to minimise sources of 
analytical variation (Optimal Conditions Precision) [24].
Data analysis 4 Data analysis techniques should be described. The power of the study 
to identify indices of biological variation should be calculated and 
presentedb [26].
Outlier analysis 4.1 (C) Outliers should be excluded from the final analysis of the data. Test 
for outliers should be applied to all levels of data (between replicate 
analysis, between samples within subject, between subjects) [25]. The 
numbers of outliers and reasons for their exclusion must be given.
Heterogeneity of variance 4.2 (C) Subjects with outlying within subject variance should be rejected from 
calculations used to determine an estimate of common true variance. 
The numbers of outliers and reasons for their exclusion must be 
givenb.
Statistical methods described and 
appropriate
4.3 (C) Statistical methods used should be appropriately identified, fit 
for purpose and referenced. Data that do not conform to a normal 
distribution should be appropriately transformed [25].
Results 5 Unified terminology [13] should be used and appropriately 
defined metadata clearly presented to enable understanding and 
transportation of the data through time and across health care 
systems.
Terminology 5.1 (D) Terms and symbols should be used to describe biological variation 
should conform standards identified by Simundic et al. [13].
Results clearly presented and 
managed
5.2 (D) Biological variation data, with derived indices, should be tabulated 
in a format that enables extraction of the key data unambiguously 
associated with a minimum data set to enable transportability of the 
data.
Power of the study and confidence limits around estimates of 
biological variation should be presented [26].
The results section should clearly identify the results of outlier 
analysis undertaken and confirm homogeneity of the data sets.
If data are stratified the variables used to enable this should be clearly 
characterised.
Discussion 6 The discussion of the data should clearly include a focus on factors 
that impact on the transportability of the data to other settings. 
Limitations and strengths of the study should be addressed.
If the data are used to set analytical performance specifications, 
derive reference change values and study individuality, the 
recommendations of Simundic et al. should be followed [13].
aMDS domains defined as A–F as shown in Table 2; bTests to determine the power of a study to identify heteroscedasticity need to be 
developed. If variances are not homogenous derived estimates of biological variation cannot be trusted, and are not representative for the 
population in which it is examined.
(Table 1: Continued)
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Table 2: Description of the minimum data set, classified in domains, required to enable safe, accurate and effective transportability of 
biological variation data across health care systems.
Domain Area for 
application
Attributes
(A) Checklist & 
database
Target – definition of analyte and measurand/s, method 
characteristics.
(B) Checklist & 
database
Population characteristics – demographics, state of well-being, 
physical/physiological characteristics, medication.
(C) Checklist & 
database
Study characteristics – study duration and design, statistical power 
of study to detect BV, model assumptions, statistical approach.
(D) Checklist & 
database
Data characteristics – estimates of biological variability, confidence 
intervals, tests for model assumptions.
(E) For database Publication details – links to the original publication.
(F) For database Data rating – new concept to be developed to indicate the quality of 
the BV data against a set of key criteria.
Discussion
There are currently no clearly defined internationally rec-
ognised standards for production, reporting and trans-
mission of BVD. If BVD are considered to be reference data 
it follows that they should be characterised and described 
with sufficient key metadata to enable valid applications 
in clinical settings. If they are to be used to set quality 
standards then users of the data must have confidence 
that the data are the product of appropriately designed 
and delivered studies and further aware of the confidence 
limits around the estimates of the variability which they 
are about to use. Delivery of confidence in both senses 
will allow appropriate contextual application of BVD sets 
in clinical settings across populations and health care 
systems (transportability).
Reviews of BVD available for a range of analytical 
targets highlight many issues in study designs and report-
ing [10–12]. This provides a major challenge to users trying 
to translate the content of individual publications into 
practice and to those attempting to collate valid data sets 
into databases for use by multiple users [17]. The prob-
lems associated with, and the needs for standardisation 
of, terminology used in publications of BV studies have 
also been highlighted by Simundic et al. [13].
The critical appraisal checklist presented here follows 
an approach that has been shown to raise standards of 
reporting of studies in other settings (STARD). The BVWG 
have attempted to identify major items, sub items to be 
considered in the design, delivery and reporting of BV 
studies. It should apply equally to laboratory based meas-
urements and quantitative physiological measurements 
(e.g., blood pressure). Compliance with the checklist will 
enable authors, reviewers and journal editors to assure 
that studies are fit for purpose, appropriately powered 
[26], share common terminology [13] and deliver estimates 
of BV accompanied by key metadata required to enable 
valid application of the BVD described [20–22]. Use of BV 
estimates accompanied by an MDS outlined in Table 2, 
delivers key metadata to enable transportability of data 
and further enable compilation of a database of BVD for 
use in setting of quality standards and other applications. 
Metadata could include the use of recognised coding 
systems to enable ease of transmission of relevant detail. 
Logical observation identifiers names and codes (LOINC) 
[27], the systemised nomenclature of medicine (SNOMED) 
[28] and the nomenclature, properties and units coding 
system (C-NPU) [29] provide examples of such. The MDS 
provides the foundation for construction of a data arche-
type to enable consistency and constancy of transmission 
of BVD through information and knowledge management 
systems as reference data. This is an important concept. 
Transportation of poorly defined and characterised BVD 
to populations that do not share characteristics may not 
only lead to setting of erroneous quality standards, but 
may also deliver patient safety issues. As an example of 
the latter if BVD are used to set reference change values, 
significance of change may be misidentified in the target 
population if they do not exhibit the same biological vari-
ation as the population from which they were derived.
The concept of scoring publications containing BVD 
has been described by Perich et  al. [17]. It is proposed 
by the BVWG that a more sophisticated score should 
be included in the MDS to accompany BVD as a quality 
measure to further aid to users as a quality measure [18]. 
This concept needs to be further developed and has paral-
lels with the scoring of medical evidence.
The checklist described here is based on expert 
opinion and provides an interim framework that may be 
used prospectively to improve future reporting of BVD and 
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retrospectively to enable critical appraisal of existing pub-
lications. It will benefit from future iterations and develop 
in the event of delivery of defined and agreed standards 
for generation and reporting of BVD. Development of spe-
cific standards for the generation, reporting and trans-
mission of BVD should also be considered by appropriate 
bodies [21]. Until such are available the detailed support-
ing information could be supplied by a series of publica-
tions similar to those developed by the IFCC and applying 
to reference values [3–8].
The practical application of this current checklist will 
be aided by current and future developments. Currently 
delivery of a pro forma set of focused questions by the 
BVWG and others will enable users to deliver a practical 
objective assessment of compliance of BVD studies with 
the high level checklist. This tool is being developed for 
future publication and to be made available online. In 
the future standardised approaches to data management 
might be greatly aided by the creation of a bespoke statis-
tical package that supports appropriate design of studies 
and data analysis. Availability and internet-based access 
to such tools and supporting information should increase 
understanding of factors that impact upon the utility of 
BVD, enable valid application of the data and drive up the 
quality of future published studies.
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